Select Language
4-1BB
4-1BB Overview
| English Name | Tumor necrosis factor receptor superfamily member 9 | Approved Drugs | 0 |
| Drugs in Clinical Trials | 78 | Target Synonym | TNFRSF9，T-cell antigen ILA，ILA，TNF Receptor Superfamily Member 9，T-Cell Antigen 4-1BB Homolog，4-1BB Ligand Receptor，CD137 Antigen，CDw137，CD137，Interleukin-Activated Receptor， Homolog Of Mouse Ly63，Tumor Necrosis Factor Receptor Superfamily， Member 9，Tumor Necrosis Factor Receptor Superfamily Member 9，Induced By Lymphocyte Activation (ILA)，Homolog Of Mouse 4-1BB，Receptor Protein 4-1BB，T Cell Antigen ILA，4-1BB |
| Highest Development Stage | Phase 3 Clinical | ||
| English Name | Tumor necrosis factor receptor superfamily member 9 |
| Target Synonym | TNFRSF9，T-cell antigen ILA，ILA，TNF Receptor Superfamily Member 9，T-Cell Antigen 4-1BB Homolog，4-1BB Ligand Receptor，CD137 Antigen，CDw137，CD137，Interleukin-Activated Receptor， Homolog Of Mouse Ly63，Tumor Necrosis Factor Receptor Superfamily， Member 9，Tumor Necrosis Factor Receptor Superfamily Member 9，Induced By Lymphocyte Activation (ILA)，Homolog Of Mouse 4-1BB，Receptor Protein 4-1BB，T Cell Antigen ILA，4-1BB |
| Approved Drugs | 0 |
| Drugs in Clinical Trials | 78 |
| Highest Development Stage | Phase 3 Clinical |
4-1BB Product List
- Product Category
Protein (20)Cell (2)Antibody (4)Kits (1)
- Product Status
Launched (27)
- Species
Human (19)Cynomolgus / Rhesus macaque (2)Mouse (3)Rabbit (1)Rat (1)Canine (1)
- Tag
Fc Tag (4)His Tag (8)Mouse IgG Fc Tag (1)His Tag & Avi Tag (5)Fc Tag & Avi Tag (1)- (7)Tag Free (1)
- Conjugate
Unconjugated (17)Biotin-labeled (6)- (3)PE Labeled (1)
Add to Cart
Total: 27
- 1
- 2
- 3
4-1BB Background
4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.
4-1BB Synonyms
TNFRSF9,4-1BB,CD137,CDw137,ILA
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Utomilumab | PF-05082566; PF-2566; PF-5082566 | Phase 3 Clinical | Pfizer Inc | Bone metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Oropharyngeal Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| Urelumab | BMS-66513; BMS-663513 | Phase 2 Clinical | Bristol-Myers Squibb Company | Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Glioblastoma; Gliosarcoma; Head and Neck Neoplasms; Leukemia; Leukemia, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Skin Melanoma; Skin Neoplasms; Solid tumours; Urinary Bladder Neoplasms | Details |
| ALG.APV-527 | ALG.APV 527; ADC-1016; ATOR-1016; ALG.APV-527; ALG-APV-527 | Phase 2 Clinical | Alligator Bioscience Ab, Aptevo Therapeutics Inc | Neoplasms; Solid tumours | Details |
| PE-0116 | PE-0116 | Phase 2 Clinical | Shanghai HyaMab Biotech Co Ltd | Solid tumours | Details |
| Delolimogene mupadenorepvec | LOAd-703 | Phase 2 Clinical | Lokon Pharma, Uppsala University | Biliary Tract Neoplasms; Colorectal Neoplasms; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms | Details |
| AGEN-2373 | AGEN-2373 | Phase 2 Clinical | Agenus Inc | Neoplasms; Pancreatic Neoplasms | Details |
| ADG-106 | ADG106; ADG-106 | Phase 2 Clinical | Adagene (Suzhou) Ltd | Lymphoma, Non-Hodgkin; Solid tumours | Details |
| Cinrebafusp alfa | PRS-343 | Phase 2 Clinical | Pieris Pharmaceuticals | Breast Neoplasms; Solid tumours; Stomach Neoplasms; Urinary Bladder Neoplasms | Details |
| CTX-471 | CTX-471 | Phase 2 Clinical | Compass Therapeutics LLC | Carcinoma, Non-Small-Cell Lung; Glioblastoma; Head and Neck Neoplasms; Melanoma; Mesothelioma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours | Details |
| Tecaginlimab | BNT-312; GEN-1042 | Phase 2 Clinical | Genmab A/S | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | Details |
| BOS-342 | PRS-342; BOS-342; PRS-342/BOS-342 | Phase 2 Clinical | Pieris Pharmaceuticals | Carcinoma, Hepatocellular; Solid tumours | Details |
| ABL-104 | ABL-104; YH-32364 | Phase 2 Clinical | Abl Bio Inc | Colorectal Neoplasms; Head and Neck Neoplasms; Solid tumours | Details |
| ABL-103 | ABL-103 | Phase 2 Clinical | Abl Bio Inc, Handok Inc | Solid tumours | Details |
| Nesfrotamig | ABL105; YH-32367 | Phase 2 Clinical | Abl Bio Inc | Breast Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Neoplasms; Solid tumours | Details |
| BAT-7111 | BAT7111; BAT-7111 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| Exlinkibart | LVGN-6051 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Carcinoma, Hepatocellular; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uveal melanoma | Details |
| LM-2417 | LM-2417; LM2417 | Phase 2 Clinical | LaNova Medicines Ltd | Solid tumours | Details |
| DSP-107 | KAHR-107; DSP-107 | Phase 2 Clinical | Kahr Medical | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Solid tumours | Details |
| DuoBody-EpCAMx4-1BB | BNT314/GEN1059; GEN-1059; GEN1059; BNT314 | Phase 2 Clinical | Biontech Se, Genmab A/S | Colorectal Neoplasms; Neoplasms; Solid tumours | Details |
| LM-24C5 | LM-24C5 | Phase 2 Clinical | LaNova Medicines Ltd | Neoplasms; Solid tumours | Details |
| IBD-0333 | IBD-0333; IBD0333 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Lymphoma, Non-Hodgkin; Neoplasms; Solid tumours | Details |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | Details |
| HK-010 | HK-010; HK010 | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms; Solid tumours | Details |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | Details |
| ARI-0002h | ARI-0002h | Phase 2 Clinical | Instituto De Salud Carlos Iii | Multiple Myeloma | Details |
| PM-1032 | PM1032; PM-1032 | Phase 2 Clinical | Shanghai Genechem Co Ltd | Neoplasms; Pancreatic Neoplasms | Details |
| Englumafusp alfa | RG-6076; RO-7227166 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
| Opamtistomig | LBL-024; LBL024 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Carcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | Details |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours | Details |
| EU-101 | EU-101; NOV-1801 | Phase 2 Clinical | Eutilex | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Prostatic Neoplasms; Solid tumours | Details |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | Details |
| Givastomig | TJ-CD4B; ABL-111; TJ-CLDN4B; TJ-033721; TJ-CD4B/ABL111 | Phase 2 Clinical | I-Mab Biopharma Co Ltd | Biliary Tract Neoplasms; Carcinoma, Pancreatic Ductal; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| Prizloncabtagene autoleucel | JNJ-4496; EXP-039; C-CAR039; C-CAR-039; C CAR 039; EXP0-039; JNJ-90014496 | Phase 2 Clinical | Cellular Biomedicine Group Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin | Details |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | Details | |
| FS-120 | FS-120 | Phase 1 Clinical | F-Star | Neoplasm Metastasis; Neoplasms | Details |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Lymphoma, B-Cell; Neoplasms; Solid tumours | Details |
| CD137/FAP bispecific agonist antibody (Boehringer Ingelheim International) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms | Details | |
| AP-601 | AP-601 | Phase 1 Clinical | AP Biosciences Inc | Neoplasms; Solid tumours | Details |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours | Details |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | Details |
| MP-0310 | MP-0310; AMG-506 | Phase 1 Clinical | Amgen Inc, Molecular Partners Ag | Solid tumours | Details |
| YH-004(Hangzhou Yuhong Medical Tech) | YH-004 | Phase 1 Clinical | Hangzhou Yuhong Medical Technology Co Ltd | Acute Kidney Injury | Details |
| hTERT-induced natural T cells therapy(Eutilex) | Phase 1 Clinical | Eutilex | Solid tumours | Details | |
| BGB-B2033 | BGB-B-2033; BGB-B2033 | Phase 1 Clinical | Beigene Guangzhou Biologics Manufacturing Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Neoplasms; Solid tumours; Stomach Neoplasms | Details |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | Details |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Cstone Pharmaceuticals, Numab Therapeutics Ag | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | Details |
| FTL-008.16 | FTL-008.16; FTL008.16 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd | Solid tumours | Details |
| NBL-028 | NBL028; NBL-028 | Phase 1 Clinical | Novarock Biotherapeutics Ltd, Shanghai Xinshi Biological Medicine Co Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Neoplasms; Ovarian Neoplasms; Solid tumours; Stomach Neoplasms; Testicular Neoplasms | Details |
| SAIL-66 | SAIL66; SAIL-66 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours | Details |
| BC 3425 | BC-3425 | Phase 1 Clinical | Wuxi BioCity | Solid tumours | Details |
| ASP1002 | ASP-1002; ASP1002 | Phase 1 Clinical | Astellas Pharma Global Development Inc | Solid tumours | Details |
| RG-6524 | RO-7616789; ALPS-12; RG6524 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Carcinoma, Neuroendocrine; Small Cell Lung Carcinoma | Details |
| SGN-BB228 | SGN-BB228; PF-08046049; BB-228; PRS-346 | Phase 1 Clinical | Pieris Pharmaceuticals | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Melanoma; Mesothelioma; Pancreatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | Details |
| IMB-071703 | IMB-071703; IMB071703 | Phase 1 Clinical | Beijng Immunoah Pharma Tech Co Ltd | Solid tumours | Details |
| ADG-206 | ADG-206 | Phase 1 Clinical | Adagene (Suzhou) Ltd | Neoplasms; Solid tumours | Details |
| TJ-C64B | TJ-C64B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Ovarian Neoplasms; Stomach Neoplasms | Details |
| ZG-033 | ZG033; HK-003 | Phase 1 Clinical | Hefei Hankemab Biotechnology Co Ltd | Neoplasms | Details |
| STA-551 | STA-551 | Phase 1 Clinical | Chugai Pharmaceutical Co Ltd | Solid tumours | Details |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | Details |
| FTL-001 | FTL001; FTL-001 | Phase 1 Clinical | Sound(Chengdu)Biopharmacauticals Co Ltd, Xikang (Wuhan) Biomedicine Co Ltd | Solid tumours | Details |
| BI-765179 | BI-765179 | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Neoplasms; Squamous Cell Carcinoma of Head and Neck | Details |
| DF-003(Dingfu Biotarget) | DF-003 | Phase 1 Clinical | Dingfu Biotarget Co Ltd | Lymphoma, Non-Hodgkin; Solid tumours | Details |
| CB-307 | CB-307; CB307 | Phase 1 Clinical | Crescendo Bioscience Inc | Neoplasms; Prostatic Neoplasms, Castration-Resistant | Details |
| RO-7122290 | RO-7122290; RG-7827 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Colorectal Neoplasms | Details |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | Details |
| HLX-35 | HLX-35; BNA035 | Phase 1 Clinical | Carcinoma, Non-Small-Cell Lung; Solid tumours | Details | |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | Details |
| HBM-7008 | HBM7008; HBM-7008; R-7008; CLN-418 | Phase 1 Clinical | Harbour Biomed | Solid tumours | Details |
| IBI-319 | IBI-319 | Phase 1 Clinical | Neoplasms | Details | |
| YH-004 | YH-004 | Phase 1 Clinical | Lymphoma, Non-Hodgkin; Neoplasms; Solid tumours | Details | |
| HOT-1030 | HOT-1030 | Phase 1 Clinical | HuaBo Biopharm Co Ltd | Solid tumours | Details |
| QL-1806 | QL-1806 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | Details |
| Cedarizumab | Phase 1 Clinical | Therawisdom Biopharma Co Ltd | Carcinoma, Transitional Cell; Melanoma; Solid tumours | Details | |
| Evunzekibart | ATOR-1017 | Phase 1 Clinical | Alligator Bioscience Ab | Neoplasms; Solid tumours | Details |
Product Reviews
유***진2026-04-21
0People LikeI purchased ACRO’s Human 4-1BB (His Tag) for our recent binding affinity studies. The most impressive aspect was the provided MALS (Multi-Angle Light Scattering) data, which gave us high confidence in the protein's oligomeric state and purity before even starting our experiments. Since 4-1BB function is highly dependent on its structural integrity, having MALS-verified molecular weight data is a huge advantage. We observed excellent consistency in our SPR (Surface Plasmon Resonance) assays with minimal lot-to-lot variation. Highly recommended for researchers requiring high-precision analytical data.- M***i2023-03-21 1People LikeI have ordered this material several times for use in Biacore/SPR assays. I have been able to obtain consistent, high-quality results with different lots of this antigen and was able to reproduce kinetic measurements reported in literature for commercial anti-4-1BB molecules. Because 4-1BB is glycosylated, the molecular weight reported by SEC-MALS is helpful for estimating Rmax for my experiments. We have also used this antigen to successfully capture anti-4-1BB out of serum in ELISAs.
- Overview
- Product List
- Product Reviews
- Clinical Drug Information
Share to: